These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 33283981)

  • 21. A 24-Week Anemia Correction Study of Daprodustat in Japanese Dialysis Patients.
    Tsubakihara Y; Akizawa T; Nangaku M; Onoue T; Yonekawa T; Matsushita H; Endo Y; Cobitz A
    Ther Apher Dial; 2020 Apr; 24(2):108-114. PubMed ID: 31306555
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Amelioration of chronic kidney disease-associated anemia by vadadustat in mice is not dependent on erythroferrone.
    Hanudel MR; Wong S; Jung G; Qiao B; Gabayan V; Zuk A; Ganz T
    Kidney Int; 2021 Jul; 100(1):79-89. PubMed ID: 33811979
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized Phase 2 trials in Japanese patients.
    Nangaku M; Farag YMK; deGoma E; Luo W; Vargo D; Khawaja Z
    Nephrol Dial Transplant; 2020 Jul; ():. PubMed ID: 32719868
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Roxadustat Treatment of Chronic Kidney Disease-Associated Anemia in Japanese Patients Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial.
    Akizawa T; Iwasaki M; Otsuka T; Reusch M; Misumi T
    Adv Ther; 2019 Jun; 36(6):1438-1454. PubMed ID: 30953333
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hypoxia-Inducible Factor Activators in Renal Anemia: Current Clinical Experience.
    Sanghani NS; Haase VH
    Adv Chronic Kidney Dis; 2019 Jul; 26(4):253-266. PubMed ID: 31477256
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase 3 Randomized Study Comparing Vadadustat with Darbepoetin Alfa for Anemia in Japanese Patients with Nondialysis-Dependent CKD.
    Nangaku M; Kondo K; Kokado Y; Ueta K; Kaneko G; Tandai T; Kawaguchi Y; Komatsu Y
    J Am Soc Nephrol; 2021 Jul; 32(7):1779-1790. PubMed ID: 33883252
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of vadadustat compared to darbepoetin alfa on anemia in patients with chronic kidney disease: a meta-analysis.
    Huang Q; Liao Z; Liu X; Xia Y; Wang J
    Int Urol Nephrol; 2023 Feb; 55(2):325-334. PubMed ID: 35960479
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Four-Week Studies of Oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia.
    Holdstock L; Meadowcroft AM; Maier R; Johnson BM; Jones D; Rastogi A; Zeig S; Lepore JJ; Cobitz AR
    J Am Soc Nephrol; 2016 Apr; 27(4):1234-44. PubMed ID: 26494831
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects.
    Akizawa T; Tsubakihara Y; Nangaku M; Endo Y; Nakajima H; Kohno T; Imai Y; Kawase N; Hara K; Lepore J; Cobitz A
    Am J Nephrol; 2017; 45(2):127-135. PubMed ID: 27978511
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preclinical Characterization of Vadadustat (AKB-6548), an Oral Small Molecule Hypoxia-Inducible Factor Prolyl-4-Hydroxylase Inhibitor, for the Potential Treatment of Renal Anemia.
    Zuk A; Si Z; Loi S; Bommegowda S; Hoivik D; Danthi S; Molnar G; Csizmadia V; Rabinowitz M
    J Pharmacol Exp Ther; 2022 Oct; 383(1):11-24. PubMed ID: 35926869
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial.
    Brigandi RA; Johnson B; Oei C; Westerman M; Olbina G; de Zoysa J; Roger SD; Sahay M; Cross N; McMahon L; Guptha V; Smolyarchuk EA; Singh N; Russ SF; Kumar S;
    Am J Kidney Dis; 2016 Jun; 67(6):861-71. PubMed ID: 26827289
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of HIF prolyl-hydroxylase inhibitor vs epoetin and darbepoetin for anemia in chronic kidney disease patients not undergoing dialysis: A network meta-analysis.
    Zheng Q; Yang H; Sun L; Wei R; Fu X; Wang Y; Huang Y; Liu YN; Liu WJ
    Pharmacol Res; 2020 Sep; 159():105020. PubMed ID: 32561478
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase 3b, multicenter, open-label, single-arm study of roxadustat (ASPEN): Operational learnings within United States dialysis organizations.
    Fishbane S; Vishnepolsky M; Oluwatosin Y; Nolen J; Zhu L; Cooper K; Young A
    Hemodial Int; 2023 Oct; 27(4):400-410. PubMed ID: 37380364
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molidustat for the treatment of anemia in Japanese patients undergoing peritoneal dialysis: a single-arm, open-label, phase 3 study.
    Akizawa T; Nobori K; Matsuda Y; Taki K; Hayashi Y; Hayasaki T; Yamamoto H
    Ther Apher Dial; 2022 Apr; 26(2):368-377. PubMed ID: 34310049
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vadadustat for Anemia in Patients with Dialysis-Dependent or Non-Dialysis-Dependent Chronic Kidney Disease.
    Bunn HF
    N Engl J Med; 2021 Oct; 385(16):e56. PubMed ID: 34644481
    [No Abstract]   [Full Text] [Related]  

  • 36. Vadadustat for Anemia in Patients with Dialysis-Dependent or Non-Dialysis-Dependent Chronic Kidney Disease. Reply.
    Chertow GM; Eckardt KU
    N Engl J Med; 2021 Oct; 385(16):e56. PubMed ID: 34644482
    [No Abstract]   [Full Text] [Related]  

  • 37. Effect of Moderate Hepatic Impairment on the Pharmacokinetics of Vadadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor.
    Chavan A; Burke L; Sawant R; Navarro-Gonzales P; Vargo D; Paulson SK
    Clin Pharmacol Drug Dev; 2021 Aug; 10(8):950-958. PubMed ID: 33661566
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In Vitro and Clinical Pharmacokinetic Studies of the Effects of Iron-containing Agents on Vadadustat, an Oral Hypoxia-inducible Factor-Prolyl Hydroxylase Inhibitor.
    Kokado Y; Kawai K; Nanjo T; Kinoshita S; Kondo K
    Clin Ther; 2021 Aug; 43(8):1408-1418.e5. PubMed ID: 34511184
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study.
    Provenzano R; Besarab A; Wright S; Dua S; Zeig S; Nguyen P; Poole L; Saikali KG; Saha G; Hemmerich S; Szczech L; Yu KH; Neff TB
    Am J Kidney Dis; 2016 Jun; 67(6):912-24. PubMed ID: 26846333
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overall Adverse Event Profile of Vadadustat versus Darbepoetin Alfa for the Treatment of Anemia Associated with Chronic Kidney Disease in Phase 3 Trials.
    Agarwal R; Anand S; Eckardt KU; Luo W; Parfrey PS; Sarnak MJ; Solinsky CM; Vargo DL; Winkelmayer WC; Chertow GM
    Am J Nephrol; 2022; 53(10):701-710. PubMed ID: 36450264
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.